$2.40
3.43% today
Nasdaq, Apr 02, 09:15 pm CET
ISIN
US98986M1036
Symbol
ZYXI

Zynex, Inc. Stock price

$2.48
-4.73 65.60% 1M
-5.35 68.33% 6M
-5.53 69.04% YTD
-10.02 80.16% 1Y
-3.73 60.06% 3Y
-7.35 74.77% 5Y
+2.35 1,812.10% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
+0.28 12.73%
ISIN
US98986M1036
Symbol
ZYXI
Sector

Key metrics

Market capitalization $79.14m
Enterprise Value $113.33m
P/E (TTM) P/E ratio 26.67
EV/FCF (TTM) EV/FCF 9.34
EV/Sales (TTM) EV/Sales 0.59
P/S ratio (TTM) P/S ratio 0.41
P/B ratio (TTM) P/B ratio 2.21
Revenue growth (TTM) Revenue growth 4.36%
Revenue (TTM) Revenue $192.35m
EBIT (operating result TTM) EBIT $5.99m
Free Cash Flow (TTM) Free Cash Flow $12.14m
Cash position $39.63m
EPS (TTM) EPS $0.09
P/E forward negative
P/S forward 0.57
EV/Sales forward 0.81
Short interest 25.09%
Show more

Is Zynex, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Zynex, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Zynex, Inc. forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Zynex, Inc. forecast:

Buy
33%
Hold
67%

Financial data from Zynex, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
192 192
4% 4%
100%
- Direct Costs 39 39
3% 3%
20%
153 153
5% 5%
80%
- Selling and Administrative Expenses 142 142
9% 9%
74%
- Research and Development Expense - -
-
-
11 11
31% 31%
6%
- Depreciation and Amortization 4.78 4.78
0% 0%
2%
EBIT (Operating Income) EBIT 5.99 5.99
44% 44%
3%
Net Profit 2.99 2.99
69% 69%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Zynex, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Zynex, Inc. Stock News

Neutral
PRNewsWire
about 4 hours ago
LOS ANGELES , April 2, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI). IF YOU SUFFERED A LOSS ON YOUR ZYNEX INVESTMENTS, CLICK HERE BEFORE MAY 19, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What...
Neutral
PRNewsWire
2 days ago
LOS ANGELES , March 31, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) have opportunity to lead the securities fraud class action lawsuit.
Neutral
GlobeNewsWire
2 days ago
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit was filed against Zynex, Inc. (NASDAQ: ZYXI) on behalf of shareholders who purchased stock between March 13, 2023, and March 11, 2025, inclusive.
More Zynex, Inc. News

Company Profile

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. Zynex was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Head office United States
CEO Thomas Sandgaard
Employees 1,000
Founded 1996
Website www.zynex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today